Clinical Experience With Fixed Bimonthly Aflibercept Dosing in Treatment-Experienced Patients With Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology - New Zealand
doi 10.2147/opth.s88624
Full Text
Abstract

Available in full text

Categories
Ophthalmology
Date
Authors
Publisher

Informa UK Limited

Related search

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Comment On: ‘One-Year Real-World Outcomes in Patients Receiving Fixed-Dosing Aflibercept for Neovascular Age-Related Macular Degeneration’

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2017English

Switching to Aflibercept Among Patients With Treatment-Resistant Neovascular Age-Related Macular Degeneration: A Systematic Review With Meta-Analysis

Clinical Ophthalmology
Ophthalmology
2017English

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

PLoS ONE
Multidisciplinary
2015English

Pss62 - Treatment Preference Drivers of Patients With Neovascular Age-Related Macular Degeneration

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Aflibercept Improves Outcome in Eyes With Poor Vision From Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2016English

Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Retinal Metabolic and Structural Alterations in Response to Aflibercept Treatment in Neovascular Age‐related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy